Dalfampridine in Egyptian Patients With Multiple Sclerosis

Summary

The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels. Moreover, further studies investigated the possible beneficial effect of dalfampridine on cognitive functions and fatigue. The main objective of this study is to investigate the effect of dalfampridine on gait impairment, cognitive functions and fatigue in a sample of Egyptian patients with multiple sclerosis.

Timeline

Start

2021-06-01

Primary completion

2023-12-01

Completion

2024-12-01

Publications

• Abdeldayem MME, Abdelnasser A, Khalil SH, Hamid E, Abousteit AM, Abushady EM, Shalash A. Effect of Dalfampridine on cognition, gait and fatigue in patients with multiple sclerosis: a randomized placebo-controlled study. Mult Scler Relat Disord. 2026 May;109:107137. doi: 10.1016/j.msard.2026.107137. Epub 2026 Mar 11.

Drugs

Indications